CRX100
Solid Tumors
Phase 1bActive
Key Facts
About BioEclipse Therapeutics
BioEclipse Therapeutics is pioneering a novel approach to treating solid tumors by combining innate and adaptive immune mechanisms within a single, engineered cell therapy. The company has two primary programs: an autologous therapy (CRX100) in Phase 1b trials and an IND-ready allogeneic, off-the-shelf therapy (CRX200). Focused on the significant unmet need in refractory solid tumors, which represent 90% of cancers, BioEclipse aims to overcome the high failure rates of current immunotherapies in this space with its potentially transformative and cost-effective platform.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |